Background-Coronary artery bypass graft surgery (CABG) compared with percutaneous coronary intervention (PCI) reduces mortality in patients with diabetes mellitus. However, prior trials compared CABG with balloon angioplasty or older generation stents, and it is not known if the gap between CABG and PCI can be reduced by newer generation drugeluting stents.
I n patients with coronary artery disease, coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI) are both treatment options. Patients with diabetes mellitus have a greater burden of atherosclerotic disease, 1,2 smaller caliber vessels with diffuse disease that often progresses rapidly, and exaggerated neointimal hyperplasia, all of which increase the likelihood of repeat revascularization. [3] [4] [5] These factors contribute to the poor outcomes (versus nondiabetic patients) in the plain old balloon angioplasty (POBA) era, 6, 7 bare metal stent (BMS) era, 8, 9 and also in the first-generation drug-eluting stent (DES) era. 10, 11 In general, CABG has been the preferred option in diabetic patients requiring revascularization. The recently published Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial showed a significant reduction in major adverse cardiovascular events (primary end point), a borderline reduction in all-cause mortality (P=0.049), and increase in stroke (P=0.03) with CABG when compared with first-generation DES in patients with diabetes mellitus, 12 in keeping with the 5-year results from the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) trial in patients with left main or 3-vessel disease. 13 All of the aforementioned data emanated from trials comparing CABG with POBA, BMS, or first-generation DES. Newer generation DES and especially cobalt-chromium everolimus-eluting stent (CoCr EES) have been shown to be efficacious and safe with significant reduction in restenosis, stent thrombosis, death, and myocardial infarction (MI) when compared with BMS [14] [15] [16] [17] and were the most efficacious and safest stent when compared with all currently available DES and even BMS in diabetic patients. 17 It is not clear whether the mortality benefit of CABG in patients with diabetes mellitus will remain significant or be of the same magnitude when compared with PCI using newer generation DES. In the absence of a specific randomized trial addressing this question, we undertook a mixed treatment comparison (MTC) analysis to further assess this hypothesis.
Methods

Study Search and Eligibility Criteria
We performed a systematic search, without language restriction, using PUBMED, EMBASE, EBSCO, Cochrane CENTRAL, CINAHL, Web of Science, Google Scholar, and conference proceedings/abstracts of the following societies: Transcatheter Cardiovascular Therapeutics, Euro-PCR, Society of Cardiovascular Angiography and Intervention, American College of Cardiology, American Heart Association, and European Society of Cardiology, for randomized clinical trials comparing revascularization modalities (PCI or CABG or comparing various DES) in patients with diabetes mellitus. The search of the databases was from their inception through December 2013 (last week) using terms that included CABG, PCI, balloon angioplasty, and the names of individual Food and Drug Administration-approved DES systems (paclitaxel-eluting stent [PES], sirolimus-eluting stent [SES], zotarolimus-eluting stent-endeavor, zotarolimus-eluting stentresolute [ZES-R], platinum-chromium everolimus-eluting stent, and CoCr EES; Table I in the Data Supplement). We checked the reference lists of original trials, review articles, and meta-analyses to find other eligible trials. The review was kept updated using automated weekly e-mail alerts, and for studies that did not report outcomes of interest, we contacted the authors via e-mail.
Inclusion criteria for eligible trials required each of the following: (1) randomized clinical trial (RCT) comparing CABG versus PCI (POBA/BMS or DES) or comparing a DES either with a different DES or with BMS in patients undergoing PCI; (2) RCTs enrolling patients with diabetes mellitus or reporting data on a diabetes mellitus subgroup; (3) RCTs enrolling ≥50 patients with follow-up of ≥6 months; and (4) RCTs reporting the outcomes of interest (below).
Exclusion criteria were the following: (1) RCTs that used biodegradable polymer stents or scaffolds or nonpolymer DES; (2) RCTs comparing stents with drug-eluting balloons or balloon angioplasty alone; and (3) stent versus stent RCTs enrolling patients with STsegment-elevation myocardial infarction as no CABG trial enrolled such patients exclusively.
Selection and Quality Assessment
Two authors (S.B., B.T.) independently searched each data source, assessed trial eligibility, extracted data, and assessed trial bias risk using the components recommended by the Cochrane Collaboration for RCTs 18 : sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; incomplete outcome data; selective outcome reporting; and other sources of bias. Trials with high or unclear risk for bias for any one of the first 3 components were considered as trials with high risk of bias. Otherwise, they were considered as trials with low risk of bias. Disagreements were resolved by discussion and consensus.
Outcomes
The primary outcome was all-cause mortality. Secondary outcomes were MI, repeat revascularization, and stroke. Data were abstracted at the longest available follow-up time point from a combination of sources: published trial data or data published in prior meta-analyses, presentations at national/international meetings, and from unpublished data from author communication.
Statistical Analyses
Mixed Treatment Comparisons
For the purpose of this analysis, 9 comparator groups were defined: CABG, POBA, BMS, PES, SES, zotarolimus-eluting stent-endeavor, ZES-R, platinum-chromium everolimus-eluting stent, and CoCr EES. Bayesian MTC models using WinBUGS 1.4.3 (MRC Biostatistics Unit, Cambridge, UK) 19 were used for each comparator versus CABG, which was used as the reference. MTC combines estimates from direct comparison from head-to-head trials as well as estimates from indirect comparisons between 2 comparators. It thus allows for comparisons of treatments not directly addressed within any of the individual trials by incorporating the indirect comparisons constructed from 2 trials that have one treatment type in common (eg, comparison of CABG versus second-generation DES using trials comparing CABG versus first-generation DES and trials comparing first-generation DES versus second-generation DES). It also has the advantage of maintaining the within-trial randomized treatment comparison of each trial while combining all available comparisons between treatments and has greater power and precision for rare events.
To account for the variability in the reported length of follow-up for each of the trials, we used the rate of outcomes per 1000 person-years to obtain the log rate ratios (RRs) of one stent relative to another, thereby incorporating the duration of the trials. A randomeffects Poisson regression model was used to perform the analysis after taking into account the correlation structure induced by the multiarm trials. 20 A burn-in phase of 50 000 simulations was used to assess convergence and a further 100 000 simulations were used for the final analyses. RRs were estimated from the median, and the accompanying 95% credibility intervals were obtained from the 2.5th and 97.5th percentiles of the posterior distribution. We used minimally informative prior distributions for log RRs (−10, 10) and for randomeffects SDs (0, 2), so the findings should be close to those obtained with frequentist methods. Network meta-analysis was conducted using WinBUGS and STATA. 21
Heterogeneity and Goodness of Fit
The validity of the Bayesian MTC models was evaluated by assessing the following characteristics of the model: (1) between trial heterogeneity; (2) goodness of fit; and (3) consistency. The variability of results
WHAT IS KNOWN
• In patients with diabetes mellitus, recent trials have shown that coronary artery bypass graft surgery (CABG) reduces mortality when compared with percutaneous coronary intervention.
• However, prior trials compared CABG with balloon angioplasty or older generation stents, and it is not known if the gap between CABG and percutaneous coronary intervention can be reduced by newer generation drug-eluting stents.
WHAT THE STUDY ADDS
• In patients with diabetes mellitus, evidence from indirect comparison shows reduced gap for cardiovascular events between CABG and percutaneous coronary intervention using second-generation drugeluting stents, especially using cobalt-chromium everolimus-eluting stent.
• CABG was associated with numerically excess stroke and percutaneous coronary intervention with cobalt-chromium everolimus-eluting stent with numerically increased repeat revascularization.
• However, this hypothesis needs to be tested in future trials.
across trials over and above chance for the MTC analysis (heterogeneity [τ 2 ]) was evaluated based on the methodology described previously, 22 with an τ 2 estimate of 0.04 interpreted as a low, 0.14 as a moderate, and 0.40 as a high degree of heterogeneity. In addition, the goodness of fit was measured, and the model was considered to provide an adequate fit to the data if 22 : (1) the mean of the residual deviance was similar to the number of data points used; (2) ≥95% of means of standardized node-based residuals were within±1.96 of the standard normal deviations; and (3) Q-Q plots of residuals fell closely around a line on visual inspection. Moreover, we evaluated the inconsistency of the MTC model, defined as the variability of results across different closed loop comparisons, by comparing the estimates from the MTC analysis with the estimates obtained from the direct comparison meta-analysis.
Direct Comparison Meta-Analysis
Intention-to-treat direct comparison meta-analysis was performed in line with recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement, 18, 23 using standard software (Stata 9.0, Stata corporation, Texas) 24 and using the random-effects model of DerSimonian and Laird. 25 Publication bias was estimated using Begg test, the weighted regression test of Egger, and visual inspection of the funnel plots. 26 
Sensitivity Analysis
Sensitivity analysis was conducted after excluding trial that did not enroll patients with multivessel disease. Multivessel disease was defined as either significant left main disease or significant stenosis in 2 or more of the epicardial coronary arteries. Further sensitivity analyses were conducted restricting trials to low risk of bias for each of the component of the quality analyses. In addition, analyses were conducted using count data rather than patient-years data and using a frequentist methodology.
Results
Study Selection and Characteristics of Included Trials
Sixty-eight randomized trials that enrolled 24 015 diabetic patients followed up for a mean of 3 years (range, 1-10 years) for a total of 71 595 patient-years of follow-up satisfied our inclusion criteria for the study ( Figure Table II in the Data Supplement). The network of comparisons is shown in Figure 1 . Of note, there was no trial comparing CABG with second-generation DES. In the Veterans Affairs Coronary Artery Revascularization in Diabetes Study (VA CARDS) trial, the majority of patients received a first-generation stent (60% SES or PES) with only 20% of patients receiving a CoCr EES stent and therefore was not considered a trial comparing newer generation DES. The FREEDOM trial was categorized as a trial comparing CABG to SES because the majority of implanted stents was SES (51% SES, 43% PES). However, a sensitivity analysis recategorizing this trial as a CABG versus PES trial did not materially change the results of the analysis (data not shown). The percentage of patients with multivessel disease in the trials was variable ( Table III in the Data Supplement). In addition, the percentage of patients with triple-vessel disease even in the CABG trials was variable (37% to 83%). Moreover, the majority of the CABG trials also enrolled variable percentage of patients with acute coronary syndromes.
Primary Outcome: All-Cause Mortality
When compared with CABG (reference RR of 1.0), PCI with PES and SES was associated with a 57% (number needed to harm=60 ) and 43% (number needed to harm=90 [50-170]) increase in the RR of all-cause mortality, respectively. However, PCI with second-generation DES such as CoCr EES (RR=1.11; 95% credibility interval, 0.67-1.84) and ZES-R (RR=1.45; 95% credibility interval, 0.31-8.81) was not associated with statistically significant increase in mortality when compared with CABG with the point estimate closer toward 1.0 (Table and Figure 2 ).
There was low heterogeneity for the analysis (τ 2 =0.04; Table IV 
Secondary Outcome: MI
Only 6 of the 14 trials comparing CABG reported the outcome of MI in the diabetic subgroup. When compared with CABG (reference RR of 1.0), the point estimate for MI for the BMS, SES, and PES all favored CABG, although none of these were statistically significant (Table and Figure 3 ). However, the point estimate for PCI with second-generation DES such as CoCr EES and ZES-R was closer to 1.0 ( Figure 3 ).
There was moderate heterogeneity for the analysis (τ 2 =0.25; Table IV 
Secondary Outcome: Repeat Revascularization
When compared with CABG (reference RR of 1.0), there was a significant increase in repeat revascularization with PCI, which progressively declined from POBA (341% increase) to BMS (218% increase) to PES (81% increase) to SES (47% increase; Table and Figure 4 ). However, for PCI with CoCr EES (RR=1.31; 95% credibility interval, 0.74-2.29), the increase in repeat revascularization (versus CABG) was not statistically significant, although the point estimate favored CABG (Figure 4 ).
There was moderate heterogeneity for the analysis (τ 2 =0.16; Table IV 
Secondary Outcome: Stroke
Only 9 trials reported stroke-related outcomes in the diabetic cohort and the vast majority of stent-to-stent comparison trials did not report this outcome. As such, this analysis is underpowered. When compared with CABG (reference RR of 1.0), the point estimate for stroke for the BMS, SES, and PES comparators all favored PCI over CABG with a nonsignificant 42%, 37%, and 45% lower stroke rate with PCI when compared with CABG (Table and Figure 5 ).
There was low heterogeneity for the analysis (τ 2 =0.13; Table IV in the Data Supplement). In addition, evaluation of the goodness of fit demonstrated adequate fit ( Table V in 
Sensitivity Analysis
Sensitivity analyses excluding trials not enrolling patients with multivessel disease yielded largely similar results Moreover, analyses restricting trials to low bias risk yielded largely similar results (Table VI in the Data Supplement). Moreover, analyses using count data showed largely similar results ( Figure 6 ).
Discussion
The results of this study with data derived from 71 595 patientyears of follow-up from randomized trials show significant excess mortality with PCI using SES and PES when compared with CABG in patients with diabetes mellitus, although this effect was attenuated with PCI using second-generation DES, especially CoCr EES. In addition, there has been a progressive relative decrease in the need for repeat revascularization, compared with CABG from POBA to BMS to PES to SES (decreasing magnitude of relative increase). This difference has become statistically nonsignificant with newer generation DES. By contrast, CABG was associated with a uniform (nonsignificant) increase in the risk of stroke across all available PCI comparators. 
Table. Median Rate (per 1000 Patient-Year of Follow-Up) of Primary and Secondary Outcomes From the Mixed Treatment Comparison Analysis of All Available Trials in the Network
CABG Versus PCI for Patients With Diabetes Mellitus
The optimal mode of revascularization in patients with diabetes mellitus has been the subject of debate for over a decade. Although it is commonly acknowledged that CABG is associated with a lower long-term risk of repeat revascularization but higher upfront risk of stroke and mortality when compared with PCI in nondiabetic patients, data from subgroup analyses of randomized trials, observational studies, and meta-analyses show a mortality benefit of CABG compared with PCI in diabetic patients. This mortality benefit indicates that the presence of diabetes mellitus with multivessel disease should be a compelling indication for CABG rather than PCI. In the FREEDOM trial, a borderline reduction in all-cause mortality (P=0.049) was seen with CABG when compared with PCI. In the SYNTAX trial, patients with denovo 3-vessel disease or unprotected left main disease, randomized to PCI using a Taxus stent versus CABG, only 25% of patients had diabetes mellitus. Yet the 5-year results are remarkably similar to those of the FREEDOM trial. At 5 years, the composite of all-cause death/MI and stroke was significantly lower in the CABG arm when compared with PCI (16.7% versus 20.8%; P=0.03), driven by a significant decrease in MI (3.8% versus 9.7%; P<0.001), numerically lower mortality (11.4% versus 13.9%; P=0.10) and numerically higher stroke (3.7% versus 2.4%; P=0.09). However, neither of these trials were powered for mortality.
There are several hypothesis put forth for reduced mortality with CABG versus PCI in diabetic patients: (1) Cardiovascular events as a function of nonculprit lesions: PCI treats significant culprit lesions only and thus diabetic patients undergoing PCI are vulnerable to plaque rupture with consequent MI and death from nonculprit lesions, which in diabetic patients are likely to be numerous. On the other hand, CABG treats culprit as well as nonculprit lesions throughout the bypassed segments, therefore providing more protection against both MI and death, resulting from subsequent plaque rupture and disease progression. (2) Cardiovascular events as a function of culprit lesions: Some of the relative benefits of CABG have been attributed to the deleterious effect of PCI. PCI with POBA was associated with a risk of acute vessel closure and late restenosis. This acute vessel closure was largely mitigated with the introduction of BMS, but the risk of restenosis in the target lesion persisted. With the introduction of DES, the risk of restenosis was substantially reduced when compared with BMS, but first-generation DES was associated with an increased risk of late stent thrombosis, especially in the high-risk patient population. [27] [28] [29] This increased risk has been attributed, in part, to hypersensitivity reactions to the polymer, resulting in inflammation and late stent malapposition. It is therefore not surprising that our analysis demonstrated a significant increase in death with PCI using SES or PES when compared with CABG.
Newer Generation DES
Our analyses show that the gap between CABG and PCI for mortality is potentially reduced with the use of newer generation stents. The analyses have to be interpreted with caution because there were no direct comparisons of CABG versus newer generation DES. However, there is evidence suggesting reduced cardiovascular events with newer generation stents when compared with BMS or first-generation DES.
Newer Generation DES Versus BMS
Newer generation stents, especially CoCr EES, have been shown to reduce the risk of stent thrombosis when compared with BMS. 16 In the Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment-Elevation Myocardial Infarction (EXAMINATION) trial of patients with ST-segment-elevation myocardial infarction, CoCr EES was associated with lower definite stent thrombosis at both 1-year 30 and 2-year followup 31 when compared with BMS. Similar results were seen in the Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia (PRODIGY) study with decrease in definite or probably stent thrombosis at 2 years with CoCr EES when compared with BMS. 32 In addition, multiple meta-analyses of RCTs have shown lower stent thrombosis with CoCr EES when compared with BMS. [15] [16] [17] Moreover, the randomized trials and meta-analyses have also shown significant reduction in target vessel revascularization with newer generation DES when compared with BMS. [15] [16] [17] Both stent thrombosis and restenosis are associated with increase in the risk of death and MI. It is therefore not surprising that in our updated analysis with data from >250 000 patient-years of follow-up from randomized trials, we have shown that CoCr EES reduced the risk of death and MI when compared with BMS. 14
Newer Generation DES Versus First-Generation DES
Multiple randomized trials and meta-analyses have shown that newer generation stents and especially CoCr EES are associated with lower rates of restenosis (especially versus PES) and stent thrombosis when compared with all other stents. [15] [16] [17] In a recent pooled analysis of A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System (SPIRIT) trials, CoCr EES was associated with reduction in death and death/ MI when compared with PES. 33 Similarly, other observational studies with large enough sample size have shown the superiority of newer generation DES over both BMS and first-generation DES. 34 In the PRODIGY trial, death or MI was lowest with CoCr EES (16%) but highest with PES (21.4%). 32 It is therefore not surprising that in our updated analysis with data from >250 000 patient-years of follow-up from randomized trials, CoCr EES reduced the risk of MI with a strong trend toward reduction in death when compared with first-generation DES. 14 The reduction in death or MI with newer generation stents is not surprising because both restenosis and stent thrombosis, which are significantly reduced by newer generation DES, are associated with significant increase in the risk of death and MI. The risk of stent thrombosis with PES at 5 years in the SYNTAX trial was 6%, a rate considered unacceptable in current day practice.
The current analysis offers several important insights. The magnitude of the relative reduction in repeat revascularization with CABG compared with PCI followed a hierarchical pattern based on the restenosis potential of the comparator with the highest risk reduction when compared with POBA and progressively less risk reduction (but statistical significant reduction) when compared with BMS, PES, and SES (in that order). The risk reduction for repeat revascularization with CABG was nonsignificant when compared with the second-generation DES, CoCr EES. Thus, the more efficacious the stent is, lesser is the absolute benefit with CABG. Similarly, although there was significant reduction in the risk of all-cause mortality with CABG when compared with SES and PES, this was no longer significant with second-generation DES and especially with CoCr EES. Newer generation DES have thinner stent struts and thinner polymer with more uniform coating of the polymer surface leading to less inflammation and thrombogenicity. 35 In addition, the fluorinated polymer surface of the CoCr EES preferentially adsorbs albumin once the stent is implanted, rendering the surface inert with less thrombogenicity even when compared with a BMS. The lack of a significant mortality difference with newer generation stents in the current analysis is likely multifactorial: (1) reduced risk of stent thrombosis; (2) reduced risk of restenosis; (3) improvement in stent implantation with meticulous attention to stent deployment in recent trials using newer generation stents; (4) stricter adherence to dual antiplatelet therapy; (5) progressive improvement in medical therapy over the years in patients undergoing PCI, thereby reducing the potential for both culprit and nonculprit lesion-related events.
Study Limitations
The study combines trial level data only and hence may not fully account for between-trial differences. However, the validity of the network model was thoroughly tested. We did not control for the duration of dual antiplatelet therapy. However, it is not clear if dual antiplatelet therapy is beneficial after CABG. The analysis does not take into account the anatomic complexity (such as SYNTAX score), which has been shown to have differential outcomes between PCI and CABG (CABG being better for intermediate to high SYNTAX score patients). However, in the FREEDOM trial, CABG was superior to PCI regardless of the SYNTAX score for the primary end point. In addition, MTC analyses aims to maintain randomization throughout all comparisons. However, in many trials, diabetic patients formed only a subgroup of enrolled patients and most did not stratify randomization based on diabetes mellitus status. Nevertheless, when baseline characteristics were reported for the diabetes mellitus subgroup, the groups were fairly balanced in the trials. Moreover, although a sensitivity analysis restricted to 3-vessel disease or left main disease is desirable, even the CABG trials enrolled variable percentage of patients with 3-vessel disease (as low as 37%) and the data on this subgroup was not separately reported in most of the trials. Of note, the CABG trials also enrolled variable percentage of patients with acute coronary syndrome, and hence, a sensitivity analyses restricting it to stable ischemic heart disease could not be performed (would have excluded most CABG trials). In addition, the CABG trials followed up patients for longer term when compared with the stent-to-stent comparison trials where the follow-up was short to intermediate. The effect of nonculprit artery disease progression may be somewhat smaller in shorter duration of follow-up. The analysis comparing CABG with second-generation DES is based on indirect comparison and is therefore hypothesis generating, which needs to be tested in future trials. Nevertheless, if future trials prove that PCI with new-generation stents is noninferior to CABG for death or MI, it may be prudent to discuss the risk of potential increase in repeat revascularization with PCI versus increased upfront risk of stroke with CABG. The PCI strategy would then be revascularization of significant culprit lesions with aggressive medical therapy applied to prevent nonculprit lesion events.
Conclusions
In patients with diabetes mellitus, the current body of evidence (from indirect comparison) shows similar mortality between CABG and PCI using second-generation DES, especially CoCr EES. CABG was associated with numerically excess stroke and PCI with CoCr EES with numerically increased repeat revascularization. This hypothesis needs to be tested in future trials.
